JNJ-95437446

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameJNJ-95437446
Drug Alias NameJNJ-95437446
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitorsDNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptorDNA topoisomerase I
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A